NRG Therapeutics
The Cambridge neuroscience company, which targets mitochondrial dysfunction
NRG Therapeutics has raised €79M across 3 funding rounds from 9 investors, most recently a Series B round in Sep 2025. Based in Cambridge, UK; active in Healthtech. Data as of 28 Oct 2026.
Cambridge, UKwww.nrgtherapeutics.com ↗
Total raised
€79M
€79,082,798
Funding rounds
3
Investors
9
distinct backers
Active since
2022-06
latest 2025-09
Funding by year
EUR raised per yearNRG Therapeutics — funding by year — interactive chart.
Data table
| NRG Therapeutics — funding by year | |
|---|---|
| 2022 | €21M |
| 2025 | €58M |
Signals
High confidenceRaise-next likelihood72
base rate 48% for Series B
- ▲ In typical raise window
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood22
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▲ Recently backed by strong-exit-track investors
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-09-09 | Series B | €58M | Brandon Capital,British Business Bank,Criteria Bio Ventures,M Ventures,Novartis Venture Fund,Omega Funds+1 more | View deal → |
| 2022-11-09 | Series A | €18M | Brandon Capital,Omega Funds,Virtual Biotech | View deal → |
| 2022-06-03 | Other | €3.1M | Biomedical Catalyst award | View deal → |
Investors
9Related news
- NRG Therapeutics Raises £16M in Series A Fundingfinsmes.com · 2022-11
- tech.eu
- cambridgeindependent.co.uk
Similar companies
same sector or countryGlobal coverage: FundingData